Intended for UK healthcare professional only
Glenmark

Effective first-line therapy for moderate to severe allergic rhinitis?1-4As you wish.

Ryaltris®
Adverse events should be reported.
Reporting forms and information can be found
at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to
Glenmark Pharmaceuticals Europe Ltd
medical_information@glenmarkpharma.com
or call 0800 458 0383

Moderate to severe allergic rhinitis (AR)

AR is common and its prevalence is increasing.5 It can be perennial (where symptoms are typically chronic) or seasonal (with intermittent symptoms triggered by various pollens or spores).5

Compared to patients with mild disease, patients with moderate to severe AR experience more frequent and longer-lasting symptoms, and are likely to have many allergenic triggers.6

These triggers include:5

...

Tree, grass and
weed pollens

...

House
dust mites

...

Animal
dander

...

Mould
spores

Contact us to request a pollen & spore poster for your practice

The ARIA guidelines define
moderate to severe AR as:7

...

Severe ongoing
nasal stuffiness with
congestion and
sinus drainage

...

Impairment of daily
activities (one or more
of sleep, work, school,
troublesome symptoms)

AR can significantly reduce patient quality of life and can affect their school or work attendance.8 Additionally, sleep can be disturbed in 50-80% of sufferers, leading to daytime tiredness, poor concentration and mood disorders.9

NICE CKS-recommended first-line treatment5

  • Intranasal corticosteroid + intranasal antihistamine is a NICE CKS-recommended first-line treatment for moderate to severe AR5
  • NICE CKS states that a combination of intranasal corticosteroid and intranasal antihistamine is more effective than an intranasal corticosteroid on its own5
  • Effective combination therapy can lead to fewer consultations10 and potential improvements in adherence4

About Ryaltris

What is Ryaltris?

Ryaltris is indicated in adults and adolescents 12 years of age and older for first-line treatment of moderate to severe nasal symptoms associated with AR.1

The active ingredients in Ryaltris are olopatadine (a potent, selective antihistamine) and mometasone furoate (a topical corticosteroid with local anti-inflammatory properties).1

Recommended dose

The Ryaltris recommended dose for adults and adolescents (12 years and older) is two actuations (sprays) in each nostril twice-daily (morning and evening).1

Please consult the Summary of Product Characteristics for more information.

Ryaltris® contains

What you can expect with Ryaltris

...
The only fixed-dose combination nasal spray for first-line treatment of moderate to severe nasal symptoms associated with AR1
...
Symptom relief within 10-15 minutes* and lasts for 24 hours with twice-daily dosing2-4
*Findings from one environmental exposure chamber study and two large randomised controlled trials2-4
...
A fine mist spray, with each bottle containing 240 actuations1,11 Recommended dose: 2 sprays in each nostril twice-daily1
Check Icon
Harnesses the synergy of two well-established and trusted products for AR, olopatadine and mometasone1,12-15
...
Provides a potential NHS acquisition cost saving of over £1.1 million a year vs. Dymista®16
...
Generally well-tolerated; the most commonly-reported adverse reactions are dysgeusia (taste disturbance), epistaxis and nasal discomfort1,2,17

Ryaltris is contraindicated in the presence of untreated, localised infection involving the nasal mucosa, such as herpes simplex, and in recent nasal surgery or trauma.1

Expert perspectives

Expert insights on AR from renowned opinion leaders? As you wish.

Glenmark understands the importance of trusted expertise and insights from leading healthcare professionals. We have therefore worked with renowned respiratory specialists to develop informative videos on allergic rhinitis.

Browse through the video selections for insights on the topics of AR diagnosis, management, treatment and dealing with concomitant asthma.

Click here to view the full selection

Expert perspectives

Support for healthcare professionals and payers

With over 40 years’ experience and accumulated pharmaceutical knowledge, Glenmark is dedicated to helping people with AR and other respiratory conditions, making us a trusted partner for the respiratory community.

We offer a broad range of support materials with tailored guidance on Ryaltris and AR for clinicians, Healthcare Organisations and patients.

For HCPs

Demonstration devices

Demonstration devices

Pollen & spore poster

Pollen & spore poster

‘How to use’ video

‘How to use’ video

Patient tear-off pad

Patient tear-off pad

Contact us to request more information about any of these items,or to arrange a visit from a Glenmark with representative.

For payers

Formulary pack

Formulary pack

Contact us for more information about payer support and how Glenmark Pharmaceuticals can help your local health area.

Support for patients

When you prescribe Ryaltris®, your patients have access to clear information and support to ensure they take their medication correctly. This information is additional to the Patient Information Leaflet (PIL) that comes in every Ryaltris® pack, and is not intended to replace the PIL.

Patient tear-off pad

Patient tear-off pad

You can provide your patients who have been prescribed Ryaltris® with a tear-off sheet covering key information and advice about their Ryaltris® treatment. Click here to download.

Website

Website

Patients prescribed Ryaltris® can access a dedicated website with information, advice and guidance to help them manage their treatment and their AR. Click here to view.

‘How to use’ video

‘How to use’ video

You can use this to facilitate training with your patients who have been prescribed Ryaltris®. The film can also be accessed from the patient website. Click the play icon to view.

References:
  1. Ryaltris Summary of Product Characteristics.
  2. Gross GN, et al. Ann Allergy Asthma Immunol 2019;122:630-638.
  3. Hampel FC, et al. Allergy Asthma Proc 2019;40(4):261–272.
  4. Patel P, et al. Ann Allergy Asthma Immunol 2019;122(2):160–166.
  5. NICE Clinical Knowledge Summary. Allergic rhinitis. Available at: https://cks.nice.org.uk/topics/ allergic-rhinitis/management/management/.
  6. Price D, et al. Clin Exp Allergy 2005;35(3):282–287.
  7. Sussman G, et al. CMAJ 2010;182(9):935–937.
  8. Scadding GK, et al. Clin Exp Allergy 2017;47:856–889.
  9. Lipworth B, et al. NPJ Prim Care Respir Med 2017;27(1):3.
  10. Price DB, et al. NJP Prim Care Respir Med 2016;26:16033.
  11. Ryaltris Patient Information Leaflet.
  12. Kamei H, et al. Arch Dermatol Res 2012;304:263–272.
  13. Marini MC, et al. Clin Ophthalmol 2023;17:3477–3489.
  14. Small CB and Teper A. Therapy 2009;6(3):393–406.
  15. Passali D, et al. Multidiscip Resp Med 2016;11:18.
  16. Data on File. Ryal/008/2023/001. August 2023.
  17. Segall N, et al. Allergy Asthma Proc 2019;40:301–310.
Ryaltris®

Ryaltris information request form

Please fill out your details and tick the boxes relevant to you if you would like to receive Ryaltris support materials, or a visit from your Glenmark representative.

Your details:

*Mandatory fields

I would like to receive:

Yes**

**By ticking ‘Yes’ you are indicating your consent to receive promotional materials from Glenmark Pharmaceuticals Europe Limited. Your details will be handled strictly in accordance with the applicable privacy laws and our privacy notice available at glenmarkpharma.com/privacy-notice/, including your right to opt out from all communication at any time. There is no obligation to hold a meeting with a representative when the form is submitted.

By clicking ‘Submit’ I consent to the use of my Personal Information provided on this form being stored and used for the purpose of following up on the request in accordance with the Glenmark Pharmaceuticals Europe Limited Terms of Use and Privacy Notice

Prescribing information and AE reporting

If you require a password please contact us here

or get in touch with your local Glenmark representative.

By clicking this link, you are leaving the Ryaltris® website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to continue, please click ‘Continue’, otherwise click ‘Stay on page.’